Ignite Creation Date:
2025-12-25 @ 12:56 AM
Ignite Modification Date:
2025-12-25 @ 11:10 PM
Study NCT ID:
NCT00971867
Status:
COMPLETED
Last Update Posted:
2022-04-08
First Post:
2009-09-03
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Head and Neck Cancer
Sponsor:
Bristol-Myers Squibb
Organization:
Study Overview
Official Title:
Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Head and Neck Cancer
Status:
COMPLETED
Status Verified Date:
2022-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to provide access to paclitaxel therapy to subjects with advanced head and neck cancer who have completed the previous late phase 2 study (CA139-388) and should have continued therapy with paclitaxel as the discretion of the investigator, and to evaluate the frequency and the severity of observed adverse reactions in treated subjects
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: